PEG-lipid micelles as drug carriers: Physiochemical attributes, formulation principles and biological implication

Journal of Drug Targeting

Volumn 23, Issue 3, 2015, Pages 222-231

  Gill, Kanwaldeep K ^a   Kaddoumi, Amal ^a   Nazzal, Sami ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Active targeting; Cancer; Cytotoxicity; Drug delivery; Drug resistance; Micelles; Nanotechnology; PEG lipid; Poorly soluble; Sustained release

Indexed keywords

DRUG CARRIER; MACROGOL; PHOSPHOLIPID; MACROGOL DERIVATIVE; MICELLE; PHOSPHATIDYLETHANOLAMINE; POLYETHYLENE GLYCOL-DISTEAROYLPHOSPHATIDYLETHANOLAMINE;

ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CHEMICAL STRUCTURE; DIAGNOSTIC IMAGING; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TARGETING; IN VITRO STUDY; INTERNALIZATION; MICELLE; MOLECULAR SIZE; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; HUMAN; MEDICINAL CHEMISTRY; PHYSICAL CHEMISTRY;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; MICELLES; MODELS, BIOLOGICAL; PHOSPHATIDYLETHANOLAMINES; PHYSICOCHEMICAL PHENOMENA; POLYETHYLENE GLYCOLS;

EID: 84923327754     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.997735     Document Type: Article

References (73)

1. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44: 235-49.
2. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-31.
3. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007;24:1-16.
4. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001;73:137-72.
5. Lasic DD. Mixed micelles in drug delivery. Nature 1992;355: 279-80.
6. La SB, Okano T, Kataoka K. Preparation and characterization of the micelle-forming polymeric drug indomethacin-incorporated poly(ethylene oxide)-poly(beta-benzyl L-aspartate) block copoly-mer micelles. J Pharm Sci 1996;85:85-90.
7. Torchilin VP, Omelyanenko VG, Papisov MI, et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta 1994;1195: 11-20.
8. Sawant RR, Sawant RM, Torchilin VP. Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anticancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity. Eur J Pharm Biopharm 2008;70:51-7.
9. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-8.
10. Schwarz KB, Mohan P, Narkewicz MR, et al. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2006;43: 499-505.
11. Webster R, Didier E, Harris P, et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 2007;35:9-16.
12. Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Des 2006;12:4669-84.
13. Naahidi S, Jafari M, Edalat F, et al. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release 2013;166: 182-94.
14. Roerdink F, Regts J, Van Leeuwen B, Scherphof G. Intrahepatic uptake and processing of intravenously injected small unilamellar phospholipid vesicles in rats. Biochim Biophys Acta 1984;770: 195-202.
15. Lukyanov AN, Gao Z, Mazzola L, Torchilin VP. Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm Res 2002;19:1424-9.
16. Wu H, Zhu L, Torchilin VP. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials 2013;34:1213-22.
17. Ashok B, Arleth L, Hjelm RP, et al. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J Pharm Sci 2004;93:2476-87.
18. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84.
19. Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? J Control Release 2012;164:265-75.
20. Kim S, Shi Y, Kim JY, et al. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opin Drug Deliv 2010;7:49-62.
21. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011;63:136-51.
22. Weissig V, Whiteman KR, Torchilin VP. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm Res 1998;15: 1552-6.
23. Remsberg CM, Zhao Y, Takemoto JK, et al. Pharmacokinetic evaluation of a DSPE-PEG2000 micellar formulation of ridafor-olimus in rat. Pharmaceutics 2012;5:81-93.
24. Ragi C, Sedaghat-Herati MR, Ouameur AA, Tajmir-Riahi HA. The effects of poly(ethylene glycol) on the solution structure of human serum albumin. Biopolymers 2005;78:231-6.
25. Li S, Garreau H, Pauvert B, et al. Enzymatic degradation of block copolymers prepared from epsilon-caprolactone and poly(ethylene glycol). Biomacromolecules 2002;3:525-30.
26. Gaucher G, Dufresne MH, Sant VP, et al. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005;109:169-88.
27. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 2004;56:1273-89.
28. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release 2004;100: 135-44.
29. Gao Z, Lukyanov AN, Chakilam AR, Torchilin VP. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing. J Drug Target 2003;11:87-92.
30. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copoly-mers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002;82:189-212.
31. Holland JW, Hui C, Cullis PR, Madden TD. Poly(ethylene glycol)-lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. Biochemistry 1996;35:2618-24.
32. Arleth L, Ashok B, Onyuksel H, et al. Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media. Langmuir 2005;21:3279-90.
33. Tao L, Hu W, Liu Y, et al. Shape-specific polymeric nanomedicine: emerging opportunities and challenges. Exp Biol Med (Maywood) 2011;236:20-9.
34. Sandstrom MC, Johansson E, Edwards K. Structure of mixed micelles formed in PEG-lipid/lipid dispersions. Langmuir 2007;23: 4192-8.
35. Johnsson M, Edwards K. Liposomes, disks, and spherical micelles: aggregate structure in mixtures of gel phase phosphatidylcholines and poly(ethylene glycol)-phospholipids. Biophys J 2003;85: 3839-47.
36. Liu J, Lee H, Allen C. Formulation of drugs in block copolymer micelles: drug loading and release. Curr Pharm Des 2006;12: 4685-701.
37. Sahib MN, Darwis Y, Peh KK, et al. Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebuliza-tion: physicochemical characterization and in vitro, in vivo evaluations. Int J Nanomedicine 2011;6:2351-66.
38. Gill KK, Kaddoumi A, Nazzal S. Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines. Eur J Pharm Sci 2012;46:64-71.
39. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001;47:113-31.
40. Mu L, Elbayoumi TA, Torchilin VP. Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int J Pharm 2005;306: 142-9.
41. Amiji M. Nanotechnology for cancer therapy. Boca Raton, FL: CRC Press; 2007.
42. Kastantin M, Ananthanarayanan B, Karmali P, et al. Effect of the lipid chain melting transition on the stability of DSPE-PEG(2000) micelles. Langmuir 2009;25:7279-86.
43. Gill KK, Nazzal S, Kaddoumi A. Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm 2011;79:276-84.
44. Sandvig K, Pust S, Skotland T, Van Deurs B. Clathrin-independent endocytosis: mechanisms and function. Curr Opin Cell Biol 2011; 23:413-20.
45. Sawant RM, Hurley JP, Salmaso S, et al. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocar-riers. Bioconjug Chem 2006;17:943-9.
46. Dabholkar RD, Sawant RM, Mongayt DA, et al. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm 2006;315:148-57.
47. Wang T, Petrenko VA, Torchilin VP. Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity. Mol Pharm 2010;7:1007-14.
48. Hayama A, Yamamoto T, Yokoyama M, et al. Polymeric micelles modified by folate-PEG-lipid for targeted drug delivery to cancer cells in vitro. J Nanosci Nanotechnol 2008;8:3085-90.
49. Musacchio T, Laquintana V, Latrofa A, et al. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol Pharm 2009;6:468-79.
50. Roby A, Erdogan S, Torchilin VP. Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur J Pharm Biopharm 2006;62:235-40.
51. Han X, Liu J, Liu M, et al. 9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro. Int J Pharm 2009;372:125-31.
52. Skidan I, Miao B, Thekkedath RV, et al. In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL. Drug Deliv 2009;16:45-51.
53. Sawant RR, Torchilin VP. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting. Mol Membr Biol 2010;27: 232-46.
54. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA 2003;100:6039-44.
55. Sawant RR, Torchilin VP. Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm 2009; 374:114-18.
56. Lukyanov AN, Gao Z, Torchilin VP. Micelles from polyethylene glycol/phosphatidylethanolamine conjugates for tumor drug delivery. J Control Release 2003;91:97-102.
57. Torchilin VP. Lipid-core micelles for targeted drug delivery. Curr Drug Deliv 2005;2:319-27.
58. Chernenko T, Sawant RR, Miljkovic M, et al. Raman microscopy for noninvasive imaging of pharmaceutical nanocarriers: intracel-lular distribution of cationic liposomes of different composition. Mol Pharm 2012;9:930-6.
59. Wang J, Mongayt D, Torchilin VP. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethyl-ene glycol)-lipid conjugate and positively charged lipids. J Drug Target 2005;13:73-80.
60. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997;40:S3-8.
61. Deng WJ, Yang XQ, Liang YJ, et al. FG020326-loaded nanopar-ticle with PEG and PDLLA improved pharmacodynamics of reversing multidrug resistance in vitro and in vivo. Acta Pharmacol Sin 2007;28:913-20.
62. Wang Y, Yu L, Han L, et al. Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int J Pharm 2007;337:63-73.
63. Alvarez-Lorenzo C, Sosnik A, Concheiro A. PEO-PPO block copolymers for passive micellar targeting and overcoming multi-drug resistance in cancer therapy. Curr Drug Targets 2011;12: 1112-30.
64. Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) 2010;5: 597-615.
65. Wang J, Qu H, Jin L, et al. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. J Pharm Sci 2011;100:2267-77.
66. Li L, Tan YB. Preparation and properties of mixed micelles made of pluronic polymer and PEG-PE. J Colloid Interface Sci 2008;317: 326-31.
67. Zhang YF, Wang JC, Bian DY, et al. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm 2010;74:467-73.
68. Roy A, Singh MS, Upadhyay P, Bhaskar S. Combined chemo-immunotherapy as a prospective strategy to combat cancer: a nanoparticle based approach. Mol Pharm 2010;7:1778-88.
69. Katragadda U, Teng Q, Rayaprolu BM, et al. Multi-drug delivery to tumor cells via micellar nanocarriers. Int J Pharm 2011;419:281-6.
70. Salmaso S, Bersani S, Pirazzini M, Caliceti P. pH-sensitive PEG-based micelles for tumor targeting. J Drug Target 2011;19:303-13.
71. Beilvert A, Cormode DP, Chaubet F, et al. Tyrosine polyethylene glycol (PEG)-micelle magnetic resonance contrast agent for the detection of lipid rich areas in atherosclerotic plaque. Magn Reson Med 2009;62:1195-201.
72. Judge A, Mcclintock K, Phelps JR, Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 2006;13:328-37.
73. Dams ET, Laverman P, Oyen WJ, et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 2000;292: 1071-9.